LYST

Across TCGA pan-cancer cohorts, LYST mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LYST data layer compared with 24 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LYST mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LYST expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where LYST mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.890	0.402	.006	15	view →
CCRCC	DFS	Tertile	IV	0.207	0.961	.024	9	view →
PDAC	DFS	Median	II,III,IV	0.277	0.449	.025	8	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.925	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LYST–LUAD (OS)

Open the LUAD breakdown →